Journal
TOXINS
Volume 9, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/toxins9020044
Keywords
Shiga toxin; Stx1; Stx2; hemolytic uremic syndrome; inhibitors; chloroquine; fluorodeoxyglucose; Mn2+
Categories
Funding
- Norwegian Cancer Society
- Research Council of Norway through its Centers of Excellence funding scheme [179571]
- South-Eastern Norway Regional Health Authority
Ask authors/readers for more resources
Shiga toxins consist of an A-moiety and five B-moieties able to bind the neutral glycosphingolipid globotriaosylceramide (Gb3) on the cell surface. To intoxicate cells efficiently, the toxin A-moiety has to be cleaved by furin and transported retrogradely to the Golgi apparatus and to the endoplasmic reticulum. The enzymatically active part of the A-moiety is then translocated to the cytosol, where it inhibits protein synthesis and in some cell types induces apoptosis. Protection of cells can be provided either by inhibiting binding of the toxin to cells or by interfering with any of the subsequent steps required for its toxic effect. In this article we provide a brief overview of the interaction of Shiga toxins with cells, describe some compounds and conditions found to protect cells against Shiga toxins, and discuss whether they might also provide protection in animals and humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available